| dc.description | STUDY OF ANTIINFLAMMATORY ACTIVITY OF FORMULTATED CREAM BETAKARBOKLOMETAram Dullah, I.O.Vlasenko, G.M. Voytenko, L.L. Davtyan Shupik National medical academy of postgraduate education Summary: The article presents the results of a study of antiexudative activity of complexed antifungal cream, based on clotrimazole, betamethasone dipropionate, metronidazole and urea, for treatment of dermatomycosis. By in vivo method (model of acute aseptic (dextran) inflammation) it was found that the formulated cream has antiinflammatory activity typical for glucocorticoids, dynamics and the value of which correspond to the activity of referent-medicine.Keywords: dermatomycosis, betamethasone diptopionate, antiexudative activity.Introduction. Last years are characterized by marked increase in the incidence of fungal diseases, foot fungal infections take one of the highest incidence of skin diseases. They are often characterized by thickening of the stratum corneum layer of the foot’s skin, cracks and inflammation, causing pain and itching. The long term of mycological process leads to profound disorders of the body, complicating other diseases and reduces the quality of life.When dermatomycosis is accompanied by inflammatory reaction of the skin combined using of antifungal agents and corticosteroids of local action is recommended. Based on pharmaco- technological, physical, chemical and biological research mild drug (MDL) for complex treatment of dermatomycoses based on clotrimazole, metronidazole, urea and betamethasone dipropionate named Betakarboklomet was developed. The purpose of the study was to investigate the anti-inflammatory activity of developed MDL .Methods. The study of MDL’s antiexudative activity conducted on a model of acute aseptic ( dextrane) inflammation by oncometric method was conducted. Exudative inflammation was assessed by measuring the volume of paw dynamics.Results and discussion.The maximum increase in the volume of inflamed foot was observed within 1 hour after introduction of dextran, averaging 0.78 ml. In the next 5 hours foot swelling gradually decreased, but the output volume is not returned.The study found that processed cream has expressed antiexudative activity, which is not significantly different from the reference product. Increase the volume of the paw of animals applied by drug Betakarboklomet was at the peak of edema (1 hour) 0,52 ± 0,02 ml , 3 h paw’s growth of volume of the original volume was 0,36 ± 0,02 ml, 5 hours - 0,20 ± 0,01 ml. The average value of MDL action for 5 hours was about 50.98 %, and for the reference product - 47.47 %.Ability of developed cream Betakarboklomet to inhibit inflammation in the early stages manifested by betamethasone dipropionate, which, according to the literature, is able to reduce the synthesis of prostaglandins , prostacyclin, and others. Thus, our study of impact of developed cream Betakarboklomet on inflammation, suggests that MDL has a strong anti-inflammatory effect ( inhibits the development of serotonin edema).Conclusions. Based on pharmacological studies of experimental inflammation induced by dextran, developed drug Betakarboklomet shows anti-inflammatory effect at the prototype. | uk-UA |
